Mesenchymal Stromal Cells for Acute Graft Versus Host Disease
NCT ID: NCT01589549
Last Updated: 2015-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
66 participants
INTERVENTIONAL
2012-04-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is hypothesised that mesenchymal stromal cell therapy will be superior
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Graft-versus-host Disease Associated Myelosuppression
NCT02829216
Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease
NCT02055625
Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT
NCT04738981
MSC for Severe aGVHD
NCT03631589
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
NCT00361049
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mesenchymal stromal cell therapy
Mesenchymal stromal cell therapy in addition to corticosteroid therapy
Mesenchymal stromal cell therapy
One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
Corticosteroid therapy
Mesenchymal stromal cell therapy
One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mesenchymal stromal cell therapy
One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-55 years
* Must be receiving a calcineurin inhibitor
Exclusion Criteria
* Corticosteroid therapy for 72 hours or greater
* ECOG score equal to or greater than 3
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Perth Hospital
OTHER
R.P.Herrmann
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
R.P.Herrmann
Director, Cell and Tissue Therapies, Royal Perth Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Duncan Purtill, MB, BS
Role: PRINCIPAL_INVESTIGATOR
Royal Perth Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Perth Hospital
Perth, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTN 2012/0174
Identifier Type: OTHER
Identifier Source: secondary_id
2011/128
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.